Literature DB >> 26831481

Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience.

Kelsey Klute1, Ersilia M DeFilippis2, Kelissa Shillingford2, John Chapin1, Maria T DeSancho3.   

Abstract

Splanchnic vein thrombosis (SVT) is an uncommon form of venous thrombosis. Management can be challenging due to underlying conditions, increased bleeding risk, and lack of evidence from clinical trials. We sought to characterize the presentation and management of patients with SVT at a large tertiary hospital. A total of 43 patients' electronic medical records were reviewed. Median age at diagnosis was 43 (18-71). Sixteen patients had isolated portal vein thrombosis (37.2 %), and 16 (37.2 %) had thrombosis involving multiple splanchnic veins. Abdominal pain was the most common clinical presentation (67.4 %). Thrombophilia was present in 18 patients (41.9 %), nine had underlying liver disease (20.9 %) and seven had inflammatory bowel disease (16.3 %). Thirty-nine (90.7 %) patients were treated with anticoagulation, and 11(25.6 %) of these patients underwent interventional procedures. Thirty (69.8 %) patients remained on indefinite anticoagulation. Results of follow-up imaging at least 1 month after diagnosis were available for 29 patients; imaging showed chronic, stable thrombosis in 14 patients (48.3 %), resolution of thrombosis in 13 patients (44.8 %) and asymptomatic progression in two patients (6.9 %). Recurrent thrombosis occurred in four patients (9.3 %). Major bleeding occurred in eight patients who received anticoagulation (18.6 %), including fatal subdural hematoma in one patient. In this cohort of patients managed by hematologists and gastroenterologists, the majority of patients were treated with anticoagulation. Interventional procedures were higher than in previously reported series. Our study strongly supports the interdisciplinary management of splanchnic venous thrombosis.

Entities:  

Keywords:  Outcome; Registries; Splanchnic circulation; Venous thrombosis

Mesh:

Substances:

Year:  2016        PMID: 26831481     DOI: 10.1007/s11239-016-1337-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  19 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Treatment of acute portal vein thrombosis by nontraditional anticoagulation.

Authors:  Melissa Martinez; Anand Tandra; Raj Vuppalanchi
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

Review 3.  Clinical approach to splanchnic vein thrombosis: risk factors and treatment.

Authors:  Nicoletta Riva; Marco P Donadini; Francesco Dentali; Alessandro Squizzato; Walter Ageno
Journal:  Thromb Res       Date:  2012-10       Impact factor: 3.944

4.  Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry.

Authors:  Walter Ageno; Nicoletta Riva; Sam Schulman; Soo Mee Bang; Maria Teresa Sartori; Elvira Grandone; Jan Beyer-Westendorf; Giovanni Barillari; Matteo Nicola Dario Di Minno; Francesco Dentali
Journal:  Semin Thromb Hemost       Date:  2013-12-31       Impact factor: 4.180

5.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

6.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

Review 7.  Splanchnic vein thrombosis in myeloproliferative neoplasms.

Authors:  Mallika Sekhar; Kathryn McVinnie; Andrew K Burroughs
Journal:  Br J Haematol       Date:  2013-07-15       Impact factor: 6.998

8.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

9.  The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Authors:  Ipek Yonal; Binnur Pinarbası; Fehmi Hindilerden; Veysel Sabri Hancer; Meliha Nalcaci; Sabahattin Kaymakoglu; Reyhan Diz-Kucukkaya
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

10.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245

View more
  1 in total

Review 1.  Anticoagulation in cirrhosis: a new paradigm?

Authors:  Filippo Leonardi; Nicola De Maria; Erica Villa
Journal:  Clin Mol Hepatol       Date:  2017-03-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.